Overview

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is a single-arm that includes two experimental arms,Selinexor(ATG-010) in Combination with Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients.To evaluate efficacy and safety of ATG-010 in combination with chemotherapy in RRMM patients received at least one prior lines of therapy
Phase:
Phase 2
Details
Lead Sponsor:
Chunyan Sun, MD
Treatments:
Cyclophosphamide
Dexamethasone
Doxorubicin
Liposomal doxorubicin